Trial Profile
A randomized phase II trial of adjuvant therapy with S-1 plus Hotyu-ekki-to (TJ41) versus S-1 alone for stage II/III gastric cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2019
Price :
$35
*
At a glance
- Drugs TJ 41 (Primary) ; Gimeracil/oteracil/tegafur
- Indications Gastric cancer
- Focus Therapeutic Use
- 10 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 21 Mar 2011 Actual initiation date (Mar 2011) added as reported by University Hospital Medical Information Network - Japan record.
- 21 Mar 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.